Next-Generation MPS I Treatment Platform

A revolutionary gene therapy approach for mucopolysaccharidosis type I (MPS I) that enables sustained, targeted, and precise correction of the iduronidase gene, overcoming the limitations of current treatments and offering a potential cure for this debilitating disease.

Current treatments for MPS I, including enzyme replacement therapy and bone marrow transplant, have significant limitations, such as high costs, invasive procedures, and limited efficacy. The original patent disclosed a method using AAV vectors to deliver iduronidase, but this approach has its own set of limitations, including the need for repeated administrations and potential immune responses. The new inventive concept addresses these limitations by providing a next-generation platform for MPS I treatment, leveraging cutting-edge gene editing tools and novel delivery mechanisms.

The new inventive concept encompasses four distinct approaches: (1) a self-replicating vector that integrates into the albumin locus of hepatocytes, providing continuous iduronidase production; (2) a gene editing tool and template for homology-directed repair, enabling precise correction of the iduronidase gene; (3) a gene therapy approach using a fusion protein comprising iduronidase and a targeting moiety, allowing for targeted delivery to affected tissues; and (4) a microfluidic device for in vivo gene editing, minimizing off-target effects. These approaches offer a paradigm shift in MPS I treatment, enabling sustained, targeted, and precise correction of the iduronidase gene.

The new claims introduce a novel, non-obvious combination of gene editing tools, delivery mechanisms, and targeting strategies that overcome the limitations of current MPS I treatments. The use of self-replicating vectors, gene editing tools, and microfluidic devices represents a significant departure from the original patent's AAV vector-based approach.

Alternative embodiments of the inventive concept could include the use of different gene editing tools, such as CRISPR-Cas9 or base editing, or alternative delivery mechanisms, such as lipid nanoparticles or viral vectors. Variations of the gene therapy approach could involve the use of different targeting moieties or fusion proteins.

The next-generation MPS I treatment platform has significant commercial potential, targeting a market estimated to be worth over $1 billion by 2025. The platform's potential to offer a cure for MPS I could disrupt the current treatment landscape, providing a new standard of care for patients and a significant revenue stream for pharmaceutical companies.